Objective Despite the progressive increase in the number of antidepressants, many patients
with major depressive disorder continue to be symptomatic. Clearly, there is an urgent need …

Background Major depressive disorder (MDD) is a recurrent illness with high rates of
chronicity, treatment-resistance, and significant economic impact. S-Adenosylmethionine …

Major depressive disorder (MDD) is often accompanied by significant cognitive impairment,
and there are limited interventions specific to this particular symptom. S-adenosylmethionine …

Objective. To review the antidepressant efficacy of S-Adenosyl-L-Methionine (SAMe) both in
monotherapy and/or in augmentation with antidepressants to better understand its potential …

Background: The purpose of this open trial was to evaluate the safety, tolerability, and
efficacy of oral S-adenosyl-l-methionine as an antidepressant adjunct among partial and …

Despite the increasingly large array of antidepressants available to treat major depressive
disorder, patients continue to experience relatively modest response and remission rates. In …

Objective To assess the antidepressant efficacy of S-adenosyl methionine (SAMe), a
naturally occurring methyl donor, versus the selective serotonin reuptake inhibitor (SSRI) …

Abstract As many as 29% to 46% of patients with major depressive disorder (MDD) show
only partial or no response to an adequate course of an antidepressant. The current practice …

Objective: To examine the comparative antidepressant efficacy of S-adenosyl-l-methionine
(SAMe) and escitalopram in a placebo-controlled, randomized, double-blind clinical trial …

Introduction‐S‐adenosyl‐l‐methionine (SAMe) is a naturally‐occurring substance which is a
major source of methyl groups in the brain. Material and methods‐We conducted a meta …